Xanthine oxidase inhibitors in heart failure where do we go from here?

Circulation

Volumn 131, Issue 20, 2015, Pages 1741-1744

  Tamariz, Leonardo ^a,b   Hare, Joshua M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antagonists and inhibitors; Editorials; Heart failure; Nitric oxide; Uric acid; Xanthine oxidase

Indexed keywords

NITRIC OXIDE; NITROSO DERIVATIVE; REACTIVE NITROGEN SPECIES; XANTHINE OXIDASE INHIBITOR; ALLOPURINOL; XANTHINE OXIDASE;

CARDIOVASCULAR MORTALITY; CELL DAMAGE; DISEASE SEVERITY; DOWN REGULATION; ENZYME ACTIVITY; FUNCTIONAL STATUS; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE REMODELING; HUMAN; LIVER METABOLISM; MULTICENTER STUDY (TOPIC); NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANTAGONISTS AND INHIBITORS; COMPLICATION; FEMALE; HYPERURICEMIA; MALE;

ALLOPURINOL; FEMALE; HEART FAILURE; HUMANS; HYPERURICEMIA; MALE; XANTHINE OXIDASE;

EID: 84935514695     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.016379     Document Type: Review

References (24)

1. Braunwald E. The war against heart failure: the Lancet lecture. Lancet. 2015;385:812-824. doi: 10.1016/S0140-6736(14)61889-4.
2. Hare JM. Nitroso-redox balance in the cardiovascular system. N Engl J Med. 2004;351:2112-2114. doi: 10.1056/NEJMe048269.
3. Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, Marbán E, Hare JM. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation. 2001;104:2407-2411.
4. Tsukimori K, Yoshitomi T, Morokuma S, Fukushima K, Wake N. Serum uric acid levels correlate with plasma hydrogen peroxide and protein carbonyl levels in preeclampsia. Am J Hypertens. 2008;21:1343-1346. doi: 10.1038/ajh.2008.289.
5. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, Davos CH, Cicoira M, Shamim W, Kemp M, Segal R, Osterziel KJ, Leyva F, Hetzer R, Ponikowski P, Coats AJ. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation. 2003;107:1991-1997. doi: 10.1161/01.CIR.0000065637.10517.A0.
6. Zimmet JM, Hare JM. Nitroso-redox interactions in the cardiovascular system. Circulation. 2006;114:1531-1544. doi: 10.1161/CIRCULATIONAHA.105.605519.
7. Tamariz L, Harzand A, Palacio A, Verma S, Jones J, Hare J. Uric acid as a predictor of all-cause mortality in heart failure: a meta-analysis. Congest Heart Fail. 2011;17:25-30. doi: 10.1111/j.1751-7133.2011.00200.x.
8. Tamariz L, Agarwal S, Soliman EZ, Chamberlain AM, Prineas R, Folsom AR, Ambrose M, Alonso A. Association of serum uric acid with incident atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol. 2011;108:1272-1276. doi: 10.1016/j.amjcard.2011.06.043.
9. Tamariz L, Hernandez F, Bush A, Palacio A, Hare JM. Association between serum uric acid and atrial fibrillation: a systematic review and meta-analysis. Heart Rhythm. 2014;11:1102-1108. doi: 10.1016/j.hrthm.2014.04.003.
10. Jankowska EA, Ponikowska B, Majda J, Zymlinski R, Trzaska M, Reczuch K, Borodulin-Nadzieja L, Banasiak W, Ponikowski P. Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure. Int J Cardiol. 2007;115:151-155. doi: 10.1016/j.ijcard.2005.10.033.
11. Naumova AV, Chacko VP, Ouwerkerk R, Stull L, Marbán E, Weiss RG. Xanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts. Am J Physiol Heart Circ Physiol. 2006;290:H837-H843. doi: 10.1152/ajpheart.00831.2005.
12. Stull LB, Leppo MK, Szweda L, Gao WD, Marbán E. Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ Res. 2004;95:1005-1011. doi: 10.1161/01.RES.0000148635.73331.c5.
13. Hirsch GA, Bottomley PA, Gerstenblith G, Weiss RG. Allopurinol acutely increases adenosine triphosphate energy delivery in failing human hearts. J Am Coll Cardiol. 2012;59:802-808. doi: 10.1016/j.jacc.2011.10.895.
14. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114:2508-2516. doi: 10.1161/CIRCULATIONAHA.106.651117.
15. Gotsman I, Keren A, Lotan C, Zwas DR. Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival. J Card Fail. 2012;18:694-701. doi: 10.1016/j.cardfail.2012.06.528.
16. Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tamg WHW, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O'Connor CM, Goldsmith SR, Ofili EO, Saltzberg MT, Marguiles KB, Cappola TP, Konstam MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, Hernandez AF. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) study. Circulation. 2015;131:1763-1771. doi: 10.1161/CIRCULATIONAHA.114.014536.
17. Hare JM, Mangal B, Brown J, Fisher C Jr, Freudenberger R, Colucci WS, Mann DL, Liu P, Givertz MM, Schwarz RP; OPT-CHF Investigators. Impact of oxypurinol in patients with symptomatic heart failure: results of the OPT-CHF study. J Am Coll Cardiol. 2008;51:2301-2309. doi: 10.1016/j.jacc.2008.01.068.
18. Gavin AD, Struthers AD. Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart. 2005;91:749-753. doi: 10.1136/hrt.2004.040477.
19. Greig D, Alcaino H, Castro PF, Garcia L, Verdejo HE, Navarro M, López R, Mellado R, Tapia F, Gabrielli LA, Nogerol C, Chiong M, Godoy I, Lavandero S. Xanthine-oxidase inhibitors and statins in chronic heart failure: effects on vascular and functional parameters. J Heart Lung Transplant. 2011;30:408-413. doi: 10.1016/j.healun.2010.10.003.
20. Nasr G, Maurice C. Allopurinol and global left myocardial function in heart failure patients. J Cardiovasc Dis Res. 2010;1:191-195. doi: 10.4103/0975-3583.74262.
21. Cingolani HE, Plastino JA, Escudero EM, Mangal B, Brown J, Pérez NG. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study. J Card Fail. 2006;12:491-498. doi: 10.1016/j.cardfail.2006.05.005.
22. Li H, Samouilov A, Liu X, Zweier JL. Characterization of the magnitude and kinetics of xanthine oxidase-catalyzed nitrate reduction: evaluation of its role in nitrite and nitric oxide generation in anoxic tissues. Biochemistry. 2003;42:1150-1159. doi: 10.1021/bi026385a.
23. Saraiva RM, Minhas KM, Raju SV, Barouch LA, Pitz E, Schuleri KH, Vandegaer K, Li D, Hare JM. Deficiency of neuronal nitric oxide synthase increases mortality and cardiac remodeling after myocardial infarction: role of nitroso-redox equilibrium. Circulation. 2005;112:3415-3422. doi: 10.1161/CIRCULATIONAHA.105.557892.
24. Burger DE, Lu X, Lei M, Xiang FL, Hammoud L, Jiang M, Wang H, Jones DL, Sims SM, Feng Q. Neuronal nitric oxide synthase protects against myocardial infarction-induced ventricular arrhythmia and mortality in mice. Circulation. 2009;120:1345-1354. doi: 10.1161/CIRCULATIONAHA.108.846402.